Facilities & Capacity

Cytiva & Pall: Chromotography, cell culture and SUS to benefit from $1.5bn boost

The investment will expand manufacturing capacity for life sciences products at thirteen Danaher Corporation sites run by Cytiva and Pall to meet customer demand.  The $1.5 billion investment is in addition to Cytiva’s $500 million growth strategy that was announced in September 2020 and  announced in January, and will fund expanding existing facilities as well as constructing new facilities in the US and the UK over the course of two years. More than $600 million will be invested in chromatography…

With $100m in hand, Kriya set to bring GMP gene therapy plant online

Kriya Therapeutics will use $100 million from a Series B funding to develop its gene therapy manufacturing platforms and says its GMP plant in North Carolina will come online this year. The Series B financing – led by Patient Square Capital, with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others – closed earlier this month. The funding will help support Kriya’s gene therapy platforms and manufacturing infrastructure, which aim to reduce the cost of…

Catalent ploughs $100m in Italian facility to up drug substance production

Catalent will add biologics drug substance production capabilities to its Italian plant, which it says will support demand from the European market. The $100 million investment will see contract development manufacturing organization (CDMO) Catalent install two 2,000 L single-use bioreactors in newly constructed manufacturing suites at its Anagni, Italy facility it acquired from Bristol Myers Squibb in June 2019. Additionally, the firm will build infrastructure required to house a further six 2,000 L single-use bioreactors and the first phase of…

Regeneron to invest $1.8bn at Tarrytown, NY campus

Regeneron will invest $1.8 billion over six years to expand its manufacturing, support, and research facilities in New York. According to a press release from the New York Governor’s office, Regeneron plans to expand its R&D facilities at the firm’s Westchester Country Campus in Tarrytown. The investment encompasses Regeneron’s plans that were announced in April to inject $480 million to construct a preclinical facility at its Tarrytown campus. “This new investment in our workforce and laboratory spaces will allow for…

Recipharm Indian plant to push global capacity to 1bn units

Recipharm will build a fill-finish facility in Uttarakhand, India increasing its fill-finish capacity to one billion sterile units per year. Contract development manufacturing organization (CDMO) Recipharm will construct the new facility on a greenfield site located near Dehradun in Uttarakhand as part of a joint project with Sobti. The Uttarakhand facility is the latest development in Recipharm’s partnership with Sobti, which began in November 2019 when the CDMO invested in Nichepharm. “This is part of our strategy to increase our…

Thermo takes aim at growing plasmid DNA manufacturing market with new plant

Thermo Fisher Scientific has set out to capture a larger share of the growing DNA therapy and RNA vaccine market with a new facility in California. The facility – a 67,000-square-foot facility located at Thermo’s Carlsbad campus – will supply plasmid DNA for drug candidates in clinical trials as well as commercial supply. The firm cited growing global demand for plasmid DNA-based therapies and vital mRNA-based vaccines as the driver for the investment. CEO Marc Casper said, “Demand for commercial plasmid DNA…

CDMO Ardena invests $35m to expand three European sites

Ardena says the investment is driven by business growth, capacity needs and its ambition to become a leading mid-sized CDMO. In partnership with GHO Capital, contract development manufacturing organization (CDMO) Ardena has invested $35 million to expand its European operations in Belgium, Sweden, and the Netherlands to ensure the firm can offer end-to-end solutions. “All expansion work is expected to be complete by Q1 in 2023,” Gerjan Kemperman COO at Ardena told BioProcess Insider. The firm will expand its drug product…

Forge Bio wins GentiBio AAV vector contract

Forge Bio will develop and manufacture adeno-associated viral (AAV) vectors for GentiBio’s engineered Tregs candidates from its site in Columbus, Ohio. The deal will see contract development and manufacturing organization (CDMO) Forge Bio use its Blaze Vector production platform and HEK 293 Suspension Ignition Cells to support GentiBio’s preclinical and clinical programs. The work will be undertaken at Forge Bio’s facilities at The Hearth, Columbus, which has grown through heavy investment over the past year. “Forge has rapidly expanded our…

SP doubles fill-finish capacity with Barcelona facility

SP has opened a large-scale facility in Barcelona, Spain doubling its global manufacturing capacity for fill-finish services. SP Scientific Products (SP) said that in order to meet the increasing demand for fill-finish and lyophilization (freeze dryer) equipment, it has more than doubled its global manufacturing capacity. The new 4,000 meter Barcelona plant will be equipped to offer fill-finish services and SP is also upping its production headcount and restructuring its manufacturing processes. “This is a multi-million-euro investment including the new…

Rebranded AMRI on spending spree with LakePharma and Integrity buys

A new name, the purchase of biomanufacturer LakePharma, and the addition of fill-finish firm Integrity Bio. All in a week’s work for Curia, the CDMO previously known as AMRI. Contract development and manufacturing organization (CDMO) AMRI rebranded itself this week as Curia before announcing a double acquisition expected to boost its capacity and capabilities in the manufacturing services space. The first deal sees the CDMO acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California. Financials…